ABIVAX: Abtect minor clinical delay
Abivax announced a minor delay in patient recruitment in its eagerly awaited Ph. III Abtect study, now guiding for a study completion in Q2 2025 (prev. Q1 2025) and a read-out in Q3 2025 (prev. Q2 2025). While the delay appears to be minor and not a primary concern in our view, we are revising our
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.